Matthew W. Strobeck
3 Lakeview Terrace
Winchester, MA 01890
NBER Working Papers and Publications
|August 2006||Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA|
with Ernst R. Berndt, Adrian H. B. Gottschalk
in Innovation Policy and the Economy, Volume 6, Adam B. Jaffe, Josh Lerner and Scott Stern, editors
|October 2005||Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts|
with Tomas J. Philipson, Ernst R. Berndt, Adrian H. B. Gottschalk: w11724
The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about $11 to $13 billion. Dependent on the market power assumed of producers while having patent protection, we find that PDUFA raised consumer welfare between $5 to$19 billion; thus the combined social surplus was raised between $18 to $31 billions. Converting these econo...
|June 2005||Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA|
with Ernst R. Berndt, Adrian H. B. Gottschalk: w11425
In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market. These two missions create an inherent tension within the agency and between the agency and key stakeholders. Oftentimes, communications and interactions between regulated companies and the FDA suffer.
The focus of this research is on the interactions between the FDA and the biopharmaceutical companies that perform drug R&D. To assess the current issues and state of communication and interaction between the FDA and industry, we carried out a survey of industry leadership in R&D and regulatory positions as well as senior leadership at the FDA who have respo...
Published: Berndt, Ernst R., Adrian H. B. Gottschalk, Matthew W. Strobeck. "Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA." Innovation Policy and the Economy 6 (2006): 91-121.
|October 2004||Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process|
with Ernst R. Berndt, Adrian H. B. Gottschalk, Tomas Philipson: w10822
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors submitting applications to the FDA. While PDUFA mandated action or review times, its ultimate impacts on actual final drug approval times are unknown. We model and quantify the impact of PDUFA-I and II on drug approval times, since these approval dates are the ones most directly related to new medicines becoming available to benefit patients.
In assessing the impacts of PDUFA on drug approval times, it is noteworthy that approval times were trending downwards at 1.7% percent per year prior to implementati...
Published: Berndt, Ernst R., Adrian H. B. Gottschalk, Tomas Philipson and Matthew W. Strobeck. "Assessing The Impacts Of The Prescription Drug User Fee Acts (PDUFA) On The FDA Approval Process," Forum for Health Economics and Policy, 2005, v8, Article 2. citation courtesy of